Compare AMBO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | CDIO |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Other Consumer Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.4M |
| IPO Year | 2010 | N/A |
| Metric | AMBO | CDIO |
|---|---|---|
| Price | $1.98 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 24.3K |
| Earning Date | 08-05-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,469,000.00 | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $286.49 | ★ N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $1.47 | $0.97 |
| 52 Week High | $6.75 | $7.91 |
| Indicator | AMBO | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 37.80 |
| Support Level | $2.01 | $1.22 |
| Resistance Level | $2.55 | $2.28 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 45.24 | 36.90 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.